LitAlert ~~ GeneLit.com

    • Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing.
    • van der Giessen JAM, van Dulmen S, Velthuizen ME, van den Muijsenbergh METC, van Engelen K, Collée M, van Dalen T, Aalfs CM, Hooning MJ, Spreeuwenberg PMM, Fransen MP, Ausems MGEM.
    • Breast. 2021 Apr 22:S0960-9776(21)00367-2. doi: 10.1016/j.breast.2021.04.008. Epub ahead of print.
    • Quality of Life After Bilateral Risk-Reducing Mastectomy and Simultaneous Reconstruction Using Pre-Pectoral Silicone Implants.
    • Spindler N, Ebel F, Briest S, Wallochny S, Langer S.
    • Patient Prefer Adherence. 2021 Apr 13;15:741-750. doi: 10.2147/PPA.S303208.
  • LitAlert ~~ GeneLit.com

    • Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    • Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, Grandi G, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L.
    • Genes (Basel). 2021 Apr 21;12(5):616. doi: 10.3390/genes12050616.
    • Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
    • Hinshaw JC, Zhao LP, Brimm JE, Payne TH, Hisama FM.
    • J Genet Couns. 2021 Apr 21. doi: 10.1002/jgc4.1425. Epub ahead of print.
    • Response to letter re: ERCC3 a new ovarian cancer susceptibility gene.
    • Stradella A, del Valle J, Brunet J, Lázaro C.
    • Eur J Cancer. 2021 Apr 19. doi: 10.1016/j.ejca.2021.03.015. Epub ahead of print.
    • Letter, Comment

    Original research:

    ERCC3, a new ovarian cancer susceptibility gene?

    • Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    • Warias A, Ferguson M, Chamberlain E, Currie L, Snow N, Matheson K, Penney LS, Kieser K.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1416. Epub ahead of print.
    • Preferences for and acceptability of receiving pharmacogenomic results by mail: A focus group study with a primarily African-American cohort.
    • Chan PA, Lewis KL, Biesecker BB, Erby LH, Fasaye GA, Epps S, Biesecker LG, Turbitt E.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1424. Epub ahead of print.
    • Germline and somatic mutation profile in Cancer patients revealed by a medium-sized pan-Cancer panel.
    • Li Z, Wang H, Zhang Z, Meng X, Liu D, Tang Y.
    • Genomics. 2021 Apr 17:S0888-7543(21)00156-7. doi: 10.1016/j.ygeno.2021.04.029. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
    • Cho A, Park JY, Lee SW, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT.
    • Arch Gynecol Obstet. 2021 Apr 19. doi: 10.1007/s00404-021-06013-x. Epub ahead of print.
    • Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    • Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L.
    • Gynecol Oncol. 2021 Apr 19:S0090-8258(21)00324-3. doi: 10.1016/j.ygyno.2021.04.014. Epub ahead of print.
    • Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
    • Kim JH, Park S, Park HS, Park JS, Lee ST, Kim SW, Lee JW, Lee MH, Park SK, Noh WC, Choi DH, Han W, Jung SH.
    • Sci Rep. 2021 Apr 19;11(1):8485. doi: 10.1038/s41598-021-87792-w.
    • An overview on breast cancer genetics and recent innovations: Literature survey.
    • Ramya Sree PR, Thoppil JE.
    • Breast Dis. 2021 Apr 7. doi: 10.3233/BD-201040. Epub ahead of print.
    • Review
    • Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
    • Schwartzberg LS, Kiedrowski LA.
    • Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962.
    • Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.
    • Atci MM, Geredeli Ç, Ay S, Sakin A, Ertürk B, Seçmeler S, Arici S, Çekin R, Yasar N, Can O, Cihan S, Gümüs M.
    • Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346.
    • Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.
    • Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Alqubaishi F, Alnamnakani M, Almubarak L, Al Naeem A, Almushawah F, Alrashed M, Abedalthagafi M.
    • Oncotarget. 2021 Mar 30;12(7):686-697. doi: 10.18632/oncotarget.27909.
  • LitAlert ~~ GeneLit.com

    • Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
    • Staniszewska M, Iking J, Lückerath K, Hadaschik B, Herrmann K, Ferdinandus J, Fendler WP.
    • Nucl Med Biol. 2021 Apr 9;96-97:101-111. doi: 10.1016/j.nucmedbio.2021.03.009. Epub ahead of print.
    • Review
    • Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
    • Schick J, Ritchie RP, Restini C.
    • Breast Cancer (Auckl). 2020 Mar 24;15:1178223421995854. doi: 10.1177/1178223421995854.
  • LitAlert ~~ GeneLit.com

    • A Case Report of Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a PALB2 Mutation-Positive Woman.
    • Bonev V.
    • Am Surg. 2021 Apr 15:31348211011056. doi: 10.1177/00031348211011056. Epub ahead of print.
    • Case report
    • Germline mutations and age at onset of lung adenocarcinoma.
    • Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, Sand SR, Mejia RM, Tsou TC, Salgia R, Weitzel JN.
    • Cancer. 2021 Apr 15. doi: 10.1002/cncr.33573. Epub ahead of print.
    • Familial wild-type gastrointestinal stromal tumour in association with germline truncating variants in both SDHA and PALB2.
    • Whitworth J, Casey RT, Smith PS, Giger O, Martin JE, Clark G, Cook J, Fernando MS, Taniere P; NIHR BioResource, Maher ER.
    • Eur J Hum Genet. 2021 Apr 15. doi: 10.1038/s41431-021-00862-5. Epub ahead of print.
    • "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.
    • Reyes KG, Clark C, Gerhart M, Newson AJ, Ormond KE.
    • Fam Cancer. 2021 Apr 15. doi: 10.1007/s10689-021-00251-3. Epub ahead of print.
    • FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.
    • Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson III DM, Hickson I, Tatum NJ, Rakha EA, Madhusudan S.
    • Cancers (Basel). 2021 Apr 14;13(8):E1866. doi: 10.3390/cancers13081866.
    • Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
    • Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H.
    • Sci Rep. 2021 Apr 14;11(1):8109. doi: 10.1038/s41598-021-87645-6.
    • In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    • Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.
    • Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
    • Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
    • Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L.
    • Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992.
    • The dystonia gene THAP1 controls DNA double-strand break repair choice.
    • Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A.
    • Mol Cell. 2021 Apr 6:S1097-2765(21)00229-X. doi: 10.1016/j.molcel.2021.03.034. Epub ahead of print.
    • Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
    • Chen X, Gao Y, Zhang G, Li B, Ma T, Ma Y, Wang X.
    • J Cancer. 2021 Mar 5;12(9):2643-2653. doi: 10.7150/jca.53303.
  • LitAlert ~~ GeneLit.com

    • Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
    • Liu D, Gao Y, Li L, Chen H, Bai L, Qu Y, Zhou B, Yan Y, Zhao Y.
    • Oncol Lett. 2021 May;21(5):424. doi: 10.3892/ol.2021.12685. Epub 2021 Mar 29.
    • The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.
    • Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.
    • Cancers (Basel). 2021 Apr 15;13(8):E1894. doi: 10.3390/cancers13081894.
    • Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
    • Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D'Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK.
    • Leukemia. 2021 Apr 13. doi: 10.1038/s41375-021-01246-w. Epub ahead of print.
    • PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
    • Agarwal A, Baghmar S, Dodagoudar C, Qureshi S, Khurana A, Vaibhav V, Kumar G.
    • JCO Glob Oncol. 2021 Apr;7:506-511. doi: 10.1200/GO.20.00269.
    • Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients.
    • Ji G, Yao Q, Bao L, Zhang J, Bai Q, Zhu X, Tu X, Bi R, Zhou X.
    • Ann Transl Med. 2021 Mar;9(6):453. doi: 10.21037/atm-20-6827.
    • Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
    • Conte C, Fagotti A, Avesani G, Trombadori C, Federico A, D'Indinosante M, Giudice MT, Pelligra S, Lodoli C, Marchetti C, Ferrandina G, Scambia G, Gallotta V.
    • Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
    • Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.
    • Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R.
    • Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.
  • LitAlert ~~ GeneLit.com

    • Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.
    • Itani M, Lalwani N, Ganeshan D, Zulfiqar M, Siegel C.
    • Abdom Radiol (NY). 2021 Apr 13. doi: 10.1007/s00261-020-02911-x. Epub ahead of print.
    • Review
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 Apr 13;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub ahead of print.
    • Review
    • The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    • Tone AA, McCuaig JM, Ricker N, Boghosian T, Romagnuolo T, Stickle N, Virtanen C, Zhang T, Kim RH,Ferguson SE, May T, Laframboise S, Armel S, Demsky R, Volenik A, Stuart-McEwan T, Shaw P, Oza A, Kamel-Reid S, Stockley T, Bernardini MQ.
    • Gynecol Oncol. 2021 Apr 13:S0090-8258(21)00321-8. doi: 10.1016/j.ygyno.2021.04.011. Epub ahead of print.
    • Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
    • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke CS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P.
    • Lancet Oncol. 2021 Apr 13:S1470-2045(21)00098-X. doi: 10.1016/S1470-2045(21)00098-X. Epub ahead of print.
    • Clinical Contrubution of Next-Generation Sequencing Multi- Gene Panel Testing for BRCA Negative High Risk Breast Cancer Patients.
    • Solmaz AE, Yeniay L, Gökmen E, Zekioglu O, Haydaroglu A, Bilgen I, Özkinay F, Onay H.
    • Clin Breast Cancer. 2021 Apr 12:S1526-8209(21)00070-7. doi: 10.1016/j.clbc.2021.04.002. Epub ahead of print.
    • Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.
    • Makhnoon S, Bednar EM, Krause KJ, Peterson SK, Lopez-Olivo MA.
    • Clin Genet. 2021 Apr 12. doi: 10.1111/cge.13966. Epub ahead of print.
    • Review
    • Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
    • Park SJ, Kim HS.
    • Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.
  • LitAlert ~~ GeneLit.com

    • Cost-effectiveness of risk-based breast cancer screening: A systematic review.
    • Khan SA, Hernandez-Villafuerte KV, Muchadeyi MT, Schlander M.
    • Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33593. Epub ahead of print.
    • Review
    • Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    • Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK.
    • Gynecol Oncol. 2021 Apr 7:S0090-8258(21)00272-9. doi: 10.1016/j.ygyno.2021.04.002. Epub ahead of print.
    • Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
    • Golan T, Hammel P.
    • J Natl Compr Canc Netw. 2021 Apr 1;19(4):469-473. doi: 10.6004/jnccn.2021.7031.
    • Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
    • Zhou C, Porter N, Borges M, Gauthier C, Ferguson L, Huang B, Nanda N, He J, Laheru D, Hruban RH, Goggins M, Klein AP, Roberts NJ.
    • Pancreatology. 2021 Mar 28:S1424-3903(21)00109-5. doi: 10.1016/j.pan.2021.03.015. Epub ahead of print.
    • Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients.
    • Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X.
    • Ann Transl Med. 2021 Mar;9(5):364. doi: 10.21037/atm-20-5136.
  • LitAlert ~~ GeneLit.com

    • Hunting for Hereditary Cancers.
    • May M.
    • Clinical OMICs. 2021 Apr 9. Mar/Apr 2021; 8(2).
    • Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.
    • Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group.
    • Hered Cancer Clin Pract. 2021 Apr 9;19(1):24. doi: 10.1186/s13053-021-00180-3.